# Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update
Ticker: VKTX
Company: Viking Therapeutics
Source: Viking Therapeutics
Published: 2026-04-29 20:05 EST
Original Source URL: https://ir.vikingtherapeutics.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-24 11:05 EST — [Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-1-study-to-evaluate-novel-amyl-743d8a79) — Source: Viking Therapeutics
- 2026-06-11 11:05 EST — [Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-appointment-of-hubert-c-chen-m-d-as-chief-medical--ca51f016) — Source: Viking Therapeutics
- 2026-05-21 11:05 EST — [Viking Therapeutics to Participate at Upcoming Investor Conferences](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-239640de) — Source: Viking Therapeutics
- 2026-05-12 11:05 EST — [Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026) — Source: Viking Therapeutics
- 2026-05-05 11:05 EST — [Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-two-poster-presentations-at-european-congress-on-obesity-eco-2026) — Source: Viking Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)